menu ☰
menu ˟

Nivolumab extends OS in advanced esophageal cancer

10 Jan 2019
A randomized phase 3 trial designed to compare nivolumab with chemotherapy for patients with unresectable advanced or recurrent esophageal cancer met its primary endpoint of OS, according to a company-issued press release.Nivolumab (Opdivo, Bristol-M...

Click here to view the full article which appeared in

IPH Logo